Tactile Systems Technology Inc (NASDAQ:TCMD)
| Market Cap | 496.24M+47.6% |
| Revenue (ttm) | 350.31M+17.2% |
| Net Income | 24.86M+64.5% |
| EPS | 1.08+74.2% |
| Shares Out | 22.56M |
| PE Ratio | 20.17 |
| Forward PE | 14.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75,959.815 |
| Open | 21.80 |
| Previous Close | 22.02 |
| Day's Range | 21.66 - 22.02 |
| 52-Week Range | 14.00 - 37.77 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 40.00(+81.82%) |
| Earnings Date | Nov 2, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About TCMD
Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TCMD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TCMD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TCMD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TCMD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TCMD Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Lymphedema products | $73.63M | 40.77% |
| Private insurers and other payers | $48.79M | 27.02% |
| Medicare | $17.43M | 9.65% |
| Durable medical equipment distributors | $12.07M | 6.68% |
| Airway clearance products | $12.07M | 6.68% |
| Sales-type lease revenue | $9.21M | 5.10% |
| Veterans Administration | $7.41M | 4.10% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TCMD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TCMD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TCMD
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $15.78M |
| IWMiShares Russell 2000 ETF | $13.46M |
| DFATDimensional - US Targeted Value ETF | $6.90M |
| VXFVanguard Extended Market ETF | $6.01M |
| DFSVU.S. Small Cap Value Portfolio ETF Class Shares | $5.75M |
| IWOiShares Russell 2000 Growth ETF | $3.99M |
Estimated from each fund’s disclosed top holdings × AUM
TCMD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TCMD’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score